<DOC>
	<DOCNO>NCT00517530</DOCNO>
	<brief_summary>The primary objective phase I part study investigate safety tolerability escalate intravenous ( IV ) dose obinutuzumab give monotherapy participant CD20+ ( tumor-infiltrating lymphocytic ) Malignant Disease , include B-cell chronic lymphocytic leukemia ( CLL ) Non-Hodgkin 's Lymphoma ( NHL ) . The primary objective phase II part study investigate efficacy safety one dose obinutuzumab participant relapsed/refractory CLL NHL , turn , either indolent ( iNHL ) aggressive ( aNHL ) . It open label dose escalate study phase I open label phase II , two dos iNHL &amp; aNHL randomize ( high low dose open label treatment ) . CLL randomize one dose level use . Participants response might gain additional benefit treated opinion investigator may enrol Retreatment Period .</brief_summary>
	<brief_title>A Dose-Escalating Study Obinutuzumab Patients With B-lymphocyte Antigen ( CD20+ ) Malignant Disease ( GAUGUIN )</brief_title>
	<detailed_description />
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Adult patient , &gt; =18 year age ; Phase 1 : CD20+ malignant disease ( Bcell lymphoma BCLL ) ; Phase 2 : relapse refractory indolent NHL , relapse refractory aggressive NHL relapse refractory BCLL Have clinical indication treatment determine investigator Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy &gt; 12 week Prior use investigational antibody therapy agent within 6 month study start ; Prior use anticancer vaccine ; Prior use standard antilymphoma/leukemia therapy radiation therapy within 4 week enrollment ; Prior use MabThera ( rituximab ) within 8 week study entry ; Prior administration radioimmunotherapy 3 month prior study entry ; Central nervous system ( CNS ) lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>